FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044761581> ?p ?o ?g. }

• W2044761581 endingPage "2495" @default.
• W2044761581 startingPage "2492" @default.
• W2044761581 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jun 2002Urodynamic Effects of Terazosin Treatment for Japanese Patients With Symptomatic Benign Prostatic Hyperplasia YOSHINORI TANAKA, NAOYA MASUMORI, NAOKI ITOH, YOSHIKAZU SATO, ATSUSHI TAKAHASHI, HIROSHI OGURA, SEIJI FURUYA, and TAIJI TSUKAMOTO YOSHINORI TANAKAYOSHINORI TANAKA More articles by this author , NAOYA MASUMORINAOYA MASUMORI More articles by this author , NAOKI ITOHNAOKI ITOH More articles by this author , YOSHIKAZU SATOYOSHIKAZU SATO More articles by this author , ATSUSHI TAKAHASHIATSUSHI TAKAHASHI More articles by this author , HIROSHI OGURAHIROSHI OGURA More articles by this author , SEIJI FURUYASEIJI FURUYA More articles by this author , and TAIJI TSUKAMOTOTAIJI TSUKAMOTO More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65012-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: For treating benign prostatic hyperplasia (BPH) 5 or 10 mg. terazosin hydrochloride daily has been routinely used in North America and Europe. We investigated the urodynamic effects of 2 mg. terazosin daily on Japanese patients with symptomatic BPH using pressure flow study. Materials and Methods: A total of 20 Japanese patients 50 years old or older with symptomatic BPH underwent symptomatic and urodynamic evaluations, including pressure flow study, before and after terazosin treatment. Patients were given 1 mg. terazosin once daily for the first 7 days and they continued to receive 1 mg. terazosin twice daily for the following 3 weeks. Results: At 4 weeks after terazosin treatment the International Prostate Symptom Score, quality of life index and maximum and average flow rates were significantly improved. Pressure flow study demonstrated decreased detrusor pressure at maximum flow, and minimum detrusor pressure during voiding and urethral resistance factor after terazosin treatment. Of the 20 patients 13 (65%) showed improvement in the linear passive urethral resistance relation. There was no significant difference in the maximum W. factor before and after terazosin treatment. Conclusions: Terazosin treatment, even 2 mg. daily, urodynamically relieved bladder outlet obstruction in Japanese patients with symptomatic BPH without any changes in detrusor contractility. References 1 : The alpha adrenergic binding properties of terazosin in the human prostate and canine brain. J Urol1988; 140: 664. Abstract, Google Scholar 2 : A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol1992; 148: 1467. Link, Google Scholar 3 : A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology1996; 47: 335. Google Scholar 4 : The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur Urol1996; 30: 369. Google Scholar 5 : Clinical evaluation of terazosin hydrochloride on urinary obstruction caused by benign prostatic hypertrophy (II): double-blind comparative study compared with placebo. Jpn J Urol Surg1992; 5: 823. Google Scholar 6 : Clinical evaluation of terazosin hydrochloride on urinary obstruction caused by benign prostatic hypertrophy (I): dose-finding study. Jpn J Urol Surg1992; 5: 721. Google Scholar 7 : Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. J Urol1996; 155: 1317. Link, Google Scholar 8 : Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Urology1997; 49: 197. Google Scholar 9 : Symptom evaluation, quality of life and sexuality. In: Proceeding of the Second International Consultation on BPH. Edited by . Paris:: Scientific Communications International1993: 131. Google Scholar 10 : Symptomatic and urodynamic improvement by oral distigmine bromide in poor voiders after transurethral resection of the prostate. Urology2001; 57: 270. Google Scholar 11 : Standardization of terminology of lower urinary tract function. Neurourol Urodyn1988; 7: 403. Google Scholar 12 : Quantification of urethral resistance and bladder function during voiding, with special reference to the effects of prostate size reduction on urethral obstruction due to benign prostatic hyperplasia. Neurourol Urodyn1989; 8: 17. Google Scholar 13 : Urinary bladder function and its control in healthy females. Am J Physiol1986; 251: R225. Google Scholar 14 : Urodynamic analysis using an on-line computer. Neurourol Urodyn1989; 6: 206. Google Scholar 15 : Principles and clinical application of advanced urodynamic analysis of voiding function. Urol Clin North Am1990; 17: 553. Google Scholar 16 : Laboratory assessment of terazosin and alpha 1 blockade in prostatic hyperplasia. Urology1988; 32: 21. Google Scholar 17 : Terazosin kinetics after oral and intravenous doses. Clin Pharmacol Ther1985; 38: 423. Google Scholar 18 : Pharmacokinetics and pharmacological actions of terazosin hydrochloride, a new alpha 1 blocker (No. 1): a single dose study on Japanese healthy subjects. J Clin Ther Med1987; 3: 667. Google Scholar 19 : Efficacy of alpha-blocker (doxazosin) in BPH appraised by pressure-flow (CLIM) analysis. Neurourol Urodyn1991; 10: 295. Google Scholar From the Department of Urology, Sapporo Medical University School of Medicine, Sapporo and Urology Service, Furuya Hospital, Kitami, Japan© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 167Issue 6June 2002Page: 2492-2495 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsurinationurodynamicsprostateadrenergic antagonistsprostatic hyperplasiaMetrics Author Information YOSHINORI TANAKA More articles by this author NAOYA MASUMORI More articles by this author NAOKI ITOH More articles by this author YOSHIKAZU SATO More articles by this author ATSUSHI TAKAHASHI More articles by this author HIROSHI OGURA More articles by this author SEIJI FURUYA More articles by this author TAIJI TSUKAMOTO More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2044761581 created "2016-06-24" @default.
• W2044761581 creator A5004362750 @default.
• W2044761581 creator A5029344563 @default.
• W2044761581 creator A5050533134 @default.
• W2044761581 creator A5050676762 @default.
• W2044761581 creator A5054359199 @default.
• W2044761581 creator A5070959050 @default.
• W2044761581 creator A5076829080 @default.
• W2044761581 creator A5083918280 @default.
• W2044761581 date "2002-06-01" @default.
• W2044761581 modified "2023-10-02" @default.
• W2044761581 title "Urodynamic Effects of Terazosin Treatment for Japanese Patients With Symptomatic Benign Prostatic Hyperplasia" @default.
• W2044761581 cites W1973129456 @default.
• W2044761581 cites W1981173490 @default.
• W2044761581 cites W2031436110 @default.
• W2044761581 cites W2056571407 @default.
• W2044761581 cites W2072046604 @default.
• W2044761581 cites W208038569 @default.
• W2044761581 cites W2129450531 @default.
• W2044761581 cites W2398594357 @default.
• W2044761581 cites W2413300521 @default.
• W2044761581 cites W2419306660 @default.
• W2044761581 cites W4302172121 @default.
• W2044761581 doi "https://doi.org/10.1016/s0022-5347(05)65012-4" @default.
• W2044761581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11992065" @default.
• W2044761581 hasPublicationYear "2002" @default.
• W2044761581 type Work @default.
• W2044761581 sameAs 2044761581 @default.
• W2044761581 citedByCount "17" @default.
• W2044761581 countsByYear W20447615812013 @default.
• W2044761581 countsByYear W20447615812016 @default.
• W2044761581 countsByYear W20447615812017 @default.
• W2044761581 countsByYear W20447615812018 @default.
• W2044761581 countsByYear W20447615812023 @default.
• W2044761581 crossrefType "journal-article" @default.
• W2044761581 hasAuthorship W2044761581A5004362750 @default.
• W2044761581 hasAuthorship W2044761581A5029344563 @default.
• W2044761581 hasAuthorship W2044761581A5050533134 @default.
• W2044761581 hasAuthorship W2044761581A5050676762 @default.
• W2044761581 hasAuthorship W2044761581A5054359199 @default.
• W2044761581 hasAuthorship W2044761581A5070959050 @default.
• W2044761581 hasAuthorship W2044761581A5076829080 @default.
• W2044761581 hasAuthorship W2044761581A5083918280 @default.
• W2044761581 hasConcept C121608353 @default.
• W2044761581 hasConcept C126322002 @default.
• W2044761581 hasConcept C126894567 @default.
• W2044761581 hasConcept C2776235491 @default.
• W2044761581 hasConcept C2776547966 @default.
• W2044761581 hasConcept C2776679619 @default.
• W2044761581 hasConcept C2777562237 @default.
• W2044761581 hasConcept C2779478474 @default.
• W2044761581 hasConcept C71924100 @default.
• W2044761581 hasConceptScore W2044761581C121608353 @default.
• W2044761581 hasConceptScore W2044761581C126322002 @default.
• W2044761581 hasConceptScore W2044761581C126894567 @default.
• W2044761581 hasConceptScore W2044761581C2776235491 @default.
• W2044761581 hasConceptScore W2044761581C2776547966 @default.
• W2044761581 hasConceptScore W2044761581C2776679619 @default.
• W2044761581 hasConceptScore W2044761581C2777562237 @default.
• W2044761581 hasConceptScore W2044761581C2779478474 @default.
• W2044761581 hasConceptScore W2044761581C71924100 @default.
• W2044761581 hasIssue "6" @default.
• W2044761581 hasLocation W20447615811 @default.
• W2044761581 hasLocation W20447615812 @default.
• W2044761581 hasOpenAccess W2044761581 @default.
• W2044761581 hasPrimaryLocation W20447615811 @default.
• W2044761581 hasRelatedWork W1978630268 @default.
• W2044761581 hasRelatedWork W2013357874 @default.
• W2044761581 hasRelatedWork W2330542927 @default.
• W2044761581 hasRelatedWork W2361181619 @default.
• W2044761581 hasRelatedWork W2368894981 @default.
• W2044761581 hasRelatedWork W2373141342 @default.
• W2044761581 hasRelatedWork W2383305874 @default.
• W2044761581 hasRelatedWork W3031848428 @default.
• W2044761581 hasRelatedWork W3141442664 @default.
• W2044761581 hasRelatedWork W4382462402 @default.
• W2044761581 hasVolume "167" @default.
• W2044761581 isParatext "false" @default.
• W2044761581 isRetracted "false" @default.
• W2044761581 magId "2044761581" @default.
• W2044761581 workType "article" @default.